Trial Profile
A Phase 1, Open-Label, Parallel-Group Trial Assessing Pharmacokinetics, Safety and Tolerability of the Anti-Human Cytomegalovirus Drug Letermovir in Subjects with Hepatic Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2017
Price :
$35
*
At a glance
- Drugs Letermovir (Primary)
- Indications Cytomegalovirus infections
- Focus Pharmacokinetics
- 26 Jul 2017 New trial record
- 18 Jul 2017 Results published in the British Journal of Clinical Pharmacology.